{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T10:03:13Z","timestamp":1768039393372,"version":"3.49.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pregnancy is associated with an increased risk of venous thromboembolism (VTE), and this condition remains an important cause of maternal morbidity and mortality. Approximately 50% of gestational VTE are associated with thrombophilia. Recent studies suggest that there is also a link between thrombophilia and pregnancy loss, as well as other gestational vascular complications. Although the most compelling data derive from women with antiphospholipid antibodies, the use of anticoagulation for prevention of these complications in women with heritable thrombophilia is becoming more frequent. This article reviews the management and prevention of VTE and other complications related to the heritable thrombophilias during pregnancy, an area that remains particularly challenging because of the potential for anticoagulant-related fetal as well as maternal complications and the paucity of good-quality data upon which to base clinical decisions.<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.143","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T18:08:40Z","timestamp":1195236520000},"page":"143-150","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Management of Pregnant Women with Thrombophilia or a History of Venous Thromboembolism"],"prefix":"10.1182","volume":"2007","author":[{"given":"Shannon M.","family":"Bates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111704242942200_R1","doi-asserted-by":"crossref","unstructured":"Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:627S\u2013643S.","DOI":"10.1378\/chest.126.3_suppl.627S"},{"key":"2019111704242942200_R2","doi-asserted-by":"crossref","unstructured":"Flessa HC, Kapstrom AB, Gluck HI, Will JJ, Miller MA, Brinker BL. Placental transport of heparin. Am J Obstet Gynecol. 1965;93:570\u2013573.","DOI":"10.1016\/0002-9378(65)90518-1"},{"key":"2019111704242942200_R3","doi-asserted-by":"crossref","unstructured":"Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res. 1984;34:557\u2013560.","DOI":"10.1016\/0049-3848(84)90260-3"},{"key":"2019111704242942200_R4","doi-asserted-by":"crossref","unstructured":"Lindhoff-Last E, Kreutzenbeck H-J, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost. 2005;93:63\u201369.","DOI":"10.1160\/TH04-06-0345"},{"key":"2019111704242942200_R5","doi-asserted-by":"crossref","unstructured":"Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med. 1989;149:2233\u20132236.","DOI":"10.1001\/archinte.1989.00390100059015"},{"key":"2019111704242942200_R6","unstructured":"Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol. 2001;108:1134\u20131140."},{"key":"2019111704242942200_R7","doi-asserted-by":"crossref","unstructured":"Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia\u2014alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost. 2002;28:439\u2013445.","DOI":"10.1055\/s-2002-35284"},{"key":"2019111704242942200_R8","doi-asserted-by":"crossref","unstructured":"Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160:191\u2013196.","DOI":"10.1001\/archinte.160.2.191"},{"key":"2019111704242942200_R9","doi-asserted-by":"crossref","unstructured":"Hall JAG, Paul RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy Am J Med. 1980;68:122\u2013140.","DOI":"10.1016\/0002-9343(80)90181-3"},{"key":"2019111704242942200_R10","doi-asserted-by":"crossref","unstructured":"Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost. 2002;87:831\u2013835.","DOI":"10.1055\/s-0037-1613092"},{"key":"2019111704242942200_R11","doi-asserted-by":"crossref","unstructured":"Dempfle CE. Minor transplacental passage of fondaparinux in vivo [letter]. N Engl J Med. 2004:350:1914\u20131915.","DOI":"10.1056\/NEJM200404293501825"},{"key":"2019111704242942200_R12","doi-asserted-by":"crossref","unstructured":"Mazzolai L, Hohfeld P, Spertini F, Hayoz D, Schapira M, Duchasal MA. Fonadparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood. 2006;108:1569\u20131570.","DOI":"10.1182\/blood-2006-03-009548"},{"key":"2019111704242942200_R13","doi-asserted-by":"crossref","unstructured":"Greer IA, Nelson-Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401\u2013407.","DOI":"10.1182\/blood-2005-02-0626"},{"key":"2019111704242942200_R14","doi-asserted-by":"crossref","unstructured":"Weitz JI. Low-molecular-weight heparin. N Engl J Med. 1997;337:688\u2013698.","DOI":"10.1056\/NEJM199709043371007"},{"key":"2019111704242942200_R15","doi-asserted-by":"crossref","unstructured":"Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130:800\u2013809.","DOI":"10.7326\/0003-4819-130-10-199905180-00003"},{"key":"2019111704242942200_R16","unstructured":"Quinlan DJ, McMillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. A meta-analysis of randomized controlled trials. Ann Intern Med. 2004;160:181\u2013188."},{"key":"2019111704242942200_R17","doi-asserted-by":"crossref","unstructured":"van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2000;4:CD002001.","DOI":"10.1002\/14651858.CD002001"},{"key":"2019111704242942200_R18","doi-asserted-by":"crossref","unstructured":"Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146\u2013153.","DOI":"10.1056\/NEJMoa025313"},{"key":"2019111704242942200_R19","unstructured":"Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance\u2014United States, 1991\u20131999. MMWR Surveill Summ. 2003;62:1\u201388."},{"key":"2019111704242942200_R20","doi-asserted-by":"crossref","unstructured":"McColl MD, Ellison J, Greer IA, Tait AC, Walker ID. Prevention of the post-thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol. 2000;108:272\u2013274.","DOI":"10.1046\/j.1365-2141.2000.01877.x"},{"key":"2019111704242942200_R21","doi-asserted-by":"crossref","unstructured":"Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost. 2006;32:651\u2013658.","DOI":"10.1055\/s-2006-951293"},{"key":"2019111704242942200_R22","unstructured":"Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and leg of presentation. Obstet Gynecol Surv. 1999;54:254\u2013271."},{"key":"2019111704242942200_R23","unstructured":"Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG. 2001;108:56\u201360."},{"key":"2019111704242942200_R24","doi-asserted-by":"crossref","unstructured":"Gherman RB, Goodwin TM, Leung B, Byrne JD, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999;94:730\u2013734.","DOI":"10.1097\/00006250-199911000-00017"},{"key":"2019111704242942200_R25","doi-asserted-by":"crossref","unstructured":"Crowther MA, Spitzer K, Julian J, et al. Pharmacokinetic profile of a low-molecular weight heparin (Reviparin) in pregnant patients: a prospective cohort study. Thromb Res. 2000;98:133\u2013138.","DOI":"10.1016\/S0049-3848(99)00228-5"},{"key":"2019111704242942200_R26","doi-asserted-by":"crossref","unstructured":"Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004;191:1024\u20131029.","DOI":"10.1016\/j.ajog.2004.05.050"},{"key":"2019111704242942200_R27","doi-asserted-by":"crossref","unstructured":"Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: case series. Br J Obstet Gynaecol. 2002;109:1020\u20131024.","DOI":"10.1111\/j.1471-0528.2002.01525.x"},{"key":"2019111704242942200_R28","doi-asserted-by":"crossref","unstructured":"Montreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7\u201311.","DOI":"10.1055\/s-0038-1642376"},{"key":"2019111704242942200_R29","doi-asserted-by":"crossref","unstructured":"Anderson DR, Ginsberg JS, Burrows R, Brill-Edwards P. Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost. 1991;65:248\u2013250.","DOI":"10.1055\/s-0038-1647659"},{"key":"2019111704242942200_R30","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell MJ, Kearon C, Johnson J, et al. Brief Communication: Preoperative anticoagulant activity after bridging low-molecular weight heparin for temporary interruption of warfarin. Ann Intern Med. 2007;146:184\u2013187.","DOI":"10.7326\/0003-4819-146-3-200702060-00007"},{"key":"2019111704242942200_R31","doi-asserted-by":"crossref","unstructured":"Holst J, Lindblad B, Bergqvist D, et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in health volunteers. Blood Coagul Fibrinolys. 1994;5:795\u2013780.","DOI":"10.1097\/00001721-199410000-00018"},{"key":"2019111704242942200_R32","doi-asserted-by":"crossref","unstructured":"Frozovi K, Deveras AE, Kessler CM. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol. 2006;81:582\u2013589.","DOI":"10.1002\/ajh.20652"},{"key":"2019111704242942200_R33","doi-asserted-by":"crossref","unstructured":"Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynecological haemorrhage. BJOG. 2007;114:8\u201315.","DOI":"10.1111\/j.1471-0528.2006.01156.x"},{"key":"2019111704242942200_R34","doi-asserted-by":"crossref","unstructured":"Cheung MC, Asch MR, Gandhi S, Kingdom JCP. Temporary inferior vena caval filter use in pregnancy. J Thromb Haemost. 2005;3:1096\u20131097.","DOI":"10.1111\/j.1538-7836.2005.01299.x"},{"key":"2019111704242942200_R35","doi-asserted-by":"crossref","unstructured":"Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the Second ASRA Consensus Conference on Neuroaxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 2003;28:172\u2013197.","DOI":"10.1097\/00115550-200305000-00004"},{"key":"2019111704242942200_R36","doi-asserted-by":"crossref","unstructured":"Robertson L, Wu O, Langhorne P, et al for The Thrombosis Risk and Economic Assessment of Thrombophilia Screening (Treats) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2005;132:171\u2013196.","DOI":"10.1111\/j.1365-2141.2005.05847.x"},{"key":"2019111704242942200_R37","doi-asserted-by":"crossref","unstructured":"Pabinger I, Grafenhofer H, Kyrle PA, et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood. 2002;100:1060\u20131062.","DOI":"10.1182\/blood-2002-01-0149"},{"key":"2019111704242942200_R38","doi-asserted-by":"crossref","unstructured":"Orme ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed their infants? Br Med J. 1977;1:1564\u20131565.","DOI":"10.1136\/bmj.1.6076.1564"},{"key":"2019111704242942200_R39","doi-asserted-by":"crossref","unstructured":"McKenna R, Cole ER, Vasan V. Is warfarin sodium contraindicated in the lactating mother? J Pediatr. 1983;103:325\u2013327.","DOI":"10.1016\/S0022-3476(83)80378-3"},{"key":"2019111704242942200_R40","doi-asserted-by":"crossref","unstructured":"De Stefano V, Rossi E, Za T, Leone G. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. Semin Thromb Hemost. 2006;32:767\u2013780.","DOI":"10.1055\/s-2006-955459"},{"key":"2019111704242942200_R41","doi-asserted-by":"crossref","unstructured":"Dizon-Townson D, Miller C, Sibai B, et al for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol. 2005;106:517\u201324.","DOI":"10.1097\/01.AOG.0000173986.32528.ca"},{"key":"2019111704242942200_R42","doi-asserted-by":"crossref","unstructured":"Martinelli I. Thromboembolism in women. Semin Thromb Hemost. 2006;32:709\u2013715.","DOI":"10.1055\/s-2006-951455"},{"key":"2019111704242942200_R43","doi-asserted-by":"crossref","unstructured":"McColl M, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;8:1183\u20131188.","DOI":"10.1055\/s-0038-1657712"},{"key":"2019111704242942200_R44","doi-asserted-by":"crossref","unstructured":"Gerhardt A, Scharf RE, Beckman MW, et al. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342:374\u2013380.","DOI":"10.1056\/NEJM200002103420602"},{"key":"2019111704242942200_R45","doi-asserted-by":"crossref","unstructured":"Brill-Edwards P, Ginsberg JS, Gent M, et al for the Recurrence of Clot in This Pregnancy (ROCIT) Study Group. Safety of withholding antepartum heparin in women with a previous episode of venous thromboembolism. N Engl J Med. 2000;343:1439\u20131444.","DOI":"10.1056\/NEJM200011163432002"},{"key":"2019111704242942200_R46","unstructured":"Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated venous thromboembolism in women with a history of venous thromboembolism. J Thromb. Haemost2005;58:417\u2013418."},{"key":"2019111704242942200_R47","doi-asserted-by":"crossref","unstructured":"Hatasaka HH. Recurrent miscarriage: epidemiologic factors, definitions, and incidence. Clin Obstet Gynecol. 1994;37:625\u2013634.","DOI":"10.1097\/00003081-199409000-00016"},{"key":"2019111704242942200_R48","doi-asserted-by":"crossref","unstructured":"Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood. 2004;103:4003\u20134009.","DOI":"10.1182\/blood-2003-08-2744"},{"key":"2019111704242942200_R49","doi-asserted-by":"crossref","unstructured":"Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res. 2003;109:73\u201381.","DOI":"10.1016\/S0049-3848(03)00095-1"},{"key":"2019111704242942200_R50","doi-asserted-by":"crossref","unstructured":"Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83:693\u2013697.","DOI":"10.1055\/s-0037-1613894"},{"key":"2019111704242942200_R51","doi-asserted-by":"crossref","unstructured":"Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2003;1:433\u2013438.","DOI":"10.1046\/j.1538-7836.2003.00066.x"},{"key":"2019111704242942200_R52","doi-asserted-by":"crossref","unstructured":"Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost. 2005;3:227\u2013229.","DOI":"10.1111\/j.1538-7836.2004.01090.x"},{"key":"2019111704242942200_R53","doi-asserted-by":"crossref","unstructured":"Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103:3695\u20133699.","DOI":"10.1182\/blood-2003-12-4250"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/143\/646359\/143_150ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/143\/646359\/143_150ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:24:51Z","timestamp":1573982691000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/143\/19221\/Management-of-Pregnant-Women-with-Thrombophilia-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.143","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}